HUP0202936A2 - 1,4-Szubsztituált 4,4-diaril-ciklohexánok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk - Google Patents
1,4-Szubsztituált 4,4-diaril-ciklohexánok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásukInfo
- Publication number
- HUP0202936A2 HUP0202936A2 HU0202936A HUP0202936A HUP0202936A2 HU P0202936 A2 HUP0202936 A2 HU P0202936A2 HU 0202936 A HU0202936 A HU 0202936A HU P0202936 A HUP0202936 A HU P0202936A HU P0202936 A2 HUP0202936 A2 HU P0202936A2
- Authority
- HU
- Hungary
- Prior art keywords
- group
- nr10c
- cr4r5
- nr10r14
- optionally substituted
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 4
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 2
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 2
- -1 thiopyranyl Chemical group 0.000 abstract 2
- 102000003390 tumor necrosis factor Human genes 0.000 abstract 2
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 101001043818 Mus musculus Interleukin-31 receptor subunit alpha Proteins 0.000 abstract 1
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 230000000172 allergic effect Effects 0.000 abstract 1
- 125000004104 aryloxy group Chemical group 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- 125000001153 fluoro group Chemical group F* 0.000 abstract 1
- 125000002541 furyl group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 abstract 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 125000002950 monocyclic group Chemical group 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 abstract 1
- 125000005592 polycycloalkyl group Polymers 0.000 abstract 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 abstract 1
- 125000003107 substituted aryl group Chemical group 0.000 abstract 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 abstract 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 abstract 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 abstract 1
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 abstract 1
- 125000001544 thienyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/27—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation
- C07C45/29—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation of hydroxy groups
- C07C45/298—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation of hydroxy groups with manganese derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/56—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds from heterocyclic compounds
- C07C45/57—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds from heterocyclic compounds with oxygen as the only heteroatom
- C07C45/58—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds from heterocyclic compounds with oxygen as the only heteroatom in three-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
- C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
- C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
- C07C45/70—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form
- C07C45/71—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form being hydroxy groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
- C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
- C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
- C07C45/72—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction of compounds containing >C = O groups with the same or other compounds containing >C = O groups
- C07C45/74—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction of compounds containing >C = O groups with the same or other compounds containing >C = O groups combined with dehydration
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C47/00—Compounds having —CHO groups
- C07C47/20—Unsaturated compounds having —CHO groups bound to acyclic carbon atoms
- C07C47/277—Unsaturated compounds having —CHO groups bound to acyclic carbon atoms containing ether groups, groups, groups, or groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C47/00—Compounds having —CHO groups
- C07C47/52—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings
- C07C47/575—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings containing ether groups, groups, groups, or groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
- C07C49/84—Ketones containing a keto group bound to a six-membered aromatic ring containing ether groups, groups, groups, or groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Liquid Crystal Substances (AREA)
Abstract
A találmány (I) általános képletű PDE4 inhibitor vegyületekre, -amelynek képletében R1 az alkilrészben adott esetben szubsztituált -(CR4R5)nC(O)-O (CR4R5)mR6, -(CR4R5)nO(CR4R5)mR6, -(CR4R5)nC(O)-NR4- -(CR4R5)mR6 vagy -(CR4R5)rR6 általános képletű csoport; m 0, 1 vagy 2;n 0, 1, 2, 3 vagy 4; r 0, 1, 2, 3, 4, 5 vagy 6; R4 és R5 hidrogénatomvagy alkilcsoport; R6 hidrogénatom, metil-, hidroxi-, adott esetbenszubsztituált aril-, (aril-oxi)-alkil-, indanil-, indenil-,policikloalkil-, tetrahidrofuril-, furil-, tetrahidropiranil-,piranil-, tetrahidrotienil-, tienil-, tetrahidrotiopiranil-,tiopiranil-, cikloalkil- és telítetlen cikloalkilcsoport; X -YR2,fluoratom, -NR4R5 vagy formil-amino-csoport; Y oxigénatom vagy S(O)m,csoport; m' 0, 1 vagy 2; X2 oxigénatom vagy NR8 csoport; X4hidrogénatom, ciano-, -R9, -OR8, -C(O)R8, -C(O)OR8, -C(O)- -NR8R8,vagy -NR8R8 csoport; R2 adott esetben szubsztituált metil- vagyetilcsoport; s 0, 1, 2, 3 vagy 4; Ar adott esetben -R7 csoporttalszubsztituált fenilcsoport; Z -OR14, -OR15, -SR14, -S(O)m'R7, -S(O)2NR10R14. -NR10R14, -NR14C(O)R9, -NR10C(Y')R14, -NR10C(O)OR7, -NR10C(Y')- -NR10R14, -NR10S(O)2NR10R14, -NR10C(NCN)NR10Rl4, -NR10S(O)2-R7, -NR10C(CR4NO2)NR10R14, -NR10C(NCN)SR9, -NR10C(CR4NO2)-SR9, -NR10C(NR10)NR10R14, -NR10C(O)C(O) NR10R14 vagy -NR10C(O)C(O)OR14csoport; R8 hidrogénatom vagy -R9 csoport; R9 adott esetbenszubsztituált alkilcsoport; Rl0 -OR8 vagy -R11 csoport; R11hidrogénatom vagy adott esetben szubsztituált alkilcsoport; vagy haR10 és R11 jelentése -NR10R11 csoport, a nitrogénatommal együtt egygyűrűs csoportot képezhet; - a vegyületeket tartalmazógyógyszerkészítményekre, valamint allergiás és gyulladásos betegségekkezelésére, továbbá a tumor nekrózis faktor (TNF) termelés gátlásáravonatkozik. Ó
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14803499P | 1999-08-10 | 1999-08-10 | |
| PCT/US2000/021867 WO2001010385A2 (en) | 1999-08-10 | 2000-08-10 | 1,4-substituted 4,4-diaryl cyclohexanes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP0202936A2 true HUP0202936A2 (hu) | 2002-12-28 |
| HUP0202936A3 HUP0202936A3 (en) | 2003-11-28 |
Family
ID=22523946
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0202936A HUP0202936A3 (en) | 1999-08-10 | 2000-08-10 | 1,4-substituted 4,4-diaryl cyclohexanes, pharmaceutical compositions containing them and their use |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US6518306B1 (hu) |
| EP (1) | EP1202955A4 (hu) |
| JP (1) | JP2003522129A (hu) |
| KR (1) | KR20020022102A (hu) |
| CN (1) | CN1368952A (hu) |
| AU (1) | AU6763900A (hu) |
| BR (1) | BR0013230A (hu) |
| CA (1) | CA2378990A1 (hu) |
| CO (1) | CO5190716A1 (hu) |
| CZ (1) | CZ2002460A3 (hu) |
| HU (1) | HUP0202936A3 (hu) |
| IL (1) | IL148032A0 (hu) |
| MX (1) | MXPA02001471A (hu) |
| NO (1) | NO20020597L (hu) |
| NZ (1) | NZ516620A (hu) |
| PL (1) | PL353360A1 (hu) |
| TR (1) | TR200200347T2 (hu) |
| WO (1) | WO2001010385A2 (hu) |
| ZA (1) | ZA200201036B (hu) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002088079A2 (en) * | 2001-05-01 | 2002-11-07 | Bristol-Myers Squibb Company | Dual inhibitors of pde 7 and pde 4 |
| US20040001895A1 (en) * | 2002-06-17 | 2004-01-01 | Pfizer Inc. | Combination treatment for depression and anxiety |
| UA83266C2 (en) * | 2003-12-08 | 2008-06-25 | Уайет | Oxazole derivatives of tetracyclines |
| JP4869221B2 (ja) * | 2004-04-08 | 2012-02-08 | ワイス・エルエルシー | プロゲステロン受容体調節剤としてのチオアミド誘導体 |
| BRPI0509159B1 (pt) * | 2004-04-08 | 2014-08-26 | Wyeth Llc | Processo para preparar um composto de fenoxicicloalquila |
| US7825265B2 (en) | 2004-05-04 | 2010-11-02 | Acadia Pharmaceuticals Inc. | Compounds with activity at estrogen receptors |
| WO2005108337A2 (en) * | 2004-05-04 | 2005-11-17 | Acadia Pharmaceuticals Inc. | Compounds with activity at estrogen receptor |
| KR100694873B1 (ko) * | 2005-05-26 | 2007-03-13 | 주식회사 대인정밀 | 정수기 |
| TW200716536A (en) * | 2005-06-09 | 2007-05-01 | Chugai Pharmaceutical Co Ltd | Vitamin D compounds |
| CA2702225A1 (en) * | 2007-10-10 | 2009-04-16 | Merck Sharp & Dohme Corp. | Diphenyl substituted cycloalkanes |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993019750A1 (en) * | 1992-04-02 | 1993-10-14 | Smithkline Beecham Corporation | Compounds useful for treating allergic or inflammatory diseases |
| WO1993019748A1 (en) * | 1992-04-02 | 1993-10-14 | Smithkline Beecham Corporation | Compounds useful for treating inflammatory diseases and for inhibiting production of tumor necrosis factor |
| JPH07278038A (ja) * | 1994-04-01 | 1995-10-24 | Sumitomo Chem Co Ltd | 多官能ビニルエーテル化合物 |
| AU708349B2 (en) * | 1994-12-23 | 1999-08-05 | Smithkline Beecham Corporation | 4,4-(disubstituted)cyclohexan-1-one monomers and related compounds |
| NZ301096A (en) * | 1994-12-23 | 1999-01-28 | Smithkline Beecham Corp | 4,4-(disubstituted)cyclohexan-1-ol monomer and related derivatives; medicaments containing them |
| AR004471A1 (es) * | 1995-05-31 | 1998-12-16 | Smithkline Beecham Corp | Compuestos de ciclohexan-1-ol-4,4-disustituidos, utiles en el tratamiento de enfermedades alergicas e inflamatorias y composiciones farmaceuticas que lascontienen |
| UY25338A1 (es) * | 1998-01-07 | 2001-08-27 | Smithkline Beecham Corp | Método para tratar copd |
-
2000
- 2000-08-10 EP EP00955430A patent/EP1202955A4/en not_active Withdrawn
- 2000-08-10 NZ NZ516620A patent/NZ516620A/xx unknown
- 2000-08-10 BR BR0013230-6A patent/BR0013230A/pt not_active IP Right Cessation
- 2000-08-10 MX MXPA02001471A patent/MXPA02001471A/es unknown
- 2000-08-10 CN CN00811577A patent/CN1368952A/zh active Pending
- 2000-08-10 US US10/031,927 patent/US6518306B1/en not_active Expired - Fee Related
- 2000-08-10 KR KR1020027001848A patent/KR20020022102A/ko not_active Application Discontinuation
- 2000-08-10 CZ CZ2002460A patent/CZ2002460A3/cs unknown
- 2000-08-10 CA CA002378990A patent/CA2378990A1/en not_active Abandoned
- 2000-08-10 JP JP2001514910A patent/JP2003522129A/ja not_active Withdrawn
- 2000-08-10 PL PL00353360A patent/PL353360A1/xx not_active Application Discontinuation
- 2000-08-10 TR TR2002/00347T patent/TR200200347T2/xx unknown
- 2000-08-10 AU AU67639/00A patent/AU6763900A/en not_active Abandoned
- 2000-08-10 CO CO00059896A patent/CO5190716A1/es not_active Application Discontinuation
- 2000-08-10 HU HU0202936A patent/HUP0202936A3/hu unknown
- 2000-08-10 WO PCT/US2000/021867 patent/WO2001010385A2/en active IP Right Grant
- 2000-08-10 IL IL14803200A patent/IL148032A0/xx unknown
-
2002
- 2002-02-06 ZA ZA200201036A patent/ZA200201036B/xx unknown
- 2002-02-06 NO NO20020597A patent/NO20020597L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| KR20020022102A (ko) | 2002-03-23 |
| HUP0202936A3 (en) | 2003-11-28 |
| IL148032A0 (en) | 2002-09-12 |
| AU6763900A (en) | 2001-03-05 |
| PL353360A1 (en) | 2003-11-17 |
| CA2378990A1 (en) | 2001-02-15 |
| EP1202955A4 (en) | 2004-02-11 |
| TR200200347T2 (tr) | 2002-06-21 |
| WO2001010385A3 (en) | 2001-08-16 |
| US6518306B1 (en) | 2003-02-11 |
| WO2001010385A2 (en) | 2001-02-15 |
| EP1202955A2 (en) | 2002-05-08 |
| ZA200201036B (en) | 2003-04-30 |
| MXPA02001471A (es) | 2002-07-02 |
| NO20020597L (no) | 2002-04-03 |
| CN1368952A (zh) | 2002-09-11 |
| NZ516620A (en) | 2004-03-26 |
| NO20020597D0 (no) | 2002-02-06 |
| BR0013230A (pt) | 2002-04-23 |
| CO5190716A1 (es) | 2002-08-29 |
| JP2003522129A (ja) | 2003-07-22 |
| CZ2002460A3 (cs) | 2002-06-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0202936A2 (hu) | 1,4-Szubsztituált 4,4-diaril-ciklohexánok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| DE69428268T2 (de) | Verwendung von lokalanaesthetika zur herstellung eines arzneimittels zur behandlung von bronchialasthma | |
| HRP20030436B1 (en) | Ortho-substituted and meta-substituted bis-aryl compounds, method for the production thereof, their use as a medicament, and pharmaceutical preparations containing these compounds | |
| EA200401609A1 (ru) | Лекарственное средство для лечения диабета | |
| CA2560648A1 (en) | 1,1'-(1,2-ethynediyl)bis-benzene derivatives as ptp 1-b inhibitors | |
| RU2003134544A (ru) | Амиды антраниловой кислоты, способы их получения, их применение в качестве антиаритмических средств, а также содержащие их фармацевтические композиции | |
| RU2004100302A (ru) | Амиды антраниловой кислоты с гетероарилсульфонильной боковой цепью, способ их получения, их применение в качестве лекарственного или диагностического средства, а также содержащие их фармацевтические композиции | |
| ZA200201917B (en) | Substituted 2-dialkylaminoalkylbiphenyl derivatives. | |
| BRPI0411221A (pt) | composto, medicamento, métodos para inibir a produção de citocinas inflamatórias, e para a prevenção ou tratamento de doenças associadas com citocinas inflamatórias, método para o tratamento ou alìvio de febre, dor e/ou inflamação e, métodos para a prevenção ou tratamento de artrite reumatóide, de osteoartrite, de doença septicêmica, psorìase, doença de crohn, colite ulcerativa, diabete melito ou, hepatite | |
| EP2070919B1 (en) | Spiroquinone compound and pharmaceutical composition | |
| RU94036771A (ru) | Ингибиторы ангиогенеза и ангиогенных заболеваний | |
| DE602004015406D1 (de) | Verwendung von 3-methoxy-pregnenolon bei der herstellung eines arzneimittels zur behandlung von neurodegenerativen erkrankungen | |
| PE20021060A1 (es) | Empleo de amidas de acidos antranilicos como medicamento para el tratamiento de arritmias, asi como preparados farmaceuticos que las contienen | |
| WO2002065993A2 (en) | Use of aryl nitrone compounds in methods for treating neuropathic pain | |
| ATE416751T1 (de) | Kosmetisches und dermatologisches mittel mit magnetteilchen, dessen herstellung und verwendung | |
| HUP9900863A2 (hu) | 4,4-(Diszubsztituált)-1-ciklohexanol-származékok, a vegyületeket tartalmazó gyógyászati készítmények és alkalmazásuk | |
| Mikhailov et al. | Organoboron compounds. Allylboration of carbonyl compounds with allyl (alkyl) boranes | |
| DE502004006525D1 (de) | Verwendung von feigenkaktus (opuntia) zur herstellung eines medikaments zur behandlung von depressionen | |
| US5932591A (en) | C3 substituted trioxanes useful as antiparasitic drugs | |
| ATE216237T1 (de) | Verwendung von ropivacaine zur herstellung eines analgetikums mit minimaler motorischer blockade | |
| EP2509944B1 (en) | Novel peroxide derivatives, their process of preparation and their use in human medicine and in cosmetics for the treatment or prevention of acne | |
| ATE85521T1 (de) | Verwendung von acetyl-l-carnitin zur herstellung eines arzneimittels zur therapeutischen behandlung von schockzustaenden. | |
| CN108853111B (zh) | 一种组合物在制备治疗吉非替尼肝脏毒性药物中的应用 | |
| ATE418532T1 (de) | Carbonsäureverbindung und arzneimittel welches diese enthält | |
| US20100261684A1 (en) | Pharmaceutical combination of medication to be used by patients presenting with an acute coronary syndrome so as to stop the process and prevent a myocardial infarction |